The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Ikena Oncology P/E ratio is -3.86. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Ikena Oncology’s P/E ratio
What is Ikena Oncology P/E Ratio?
The P/E ratio of Ikena Oncology is -3.86, which represents a 61.09% increase over the same period last year. their average P / E ratio is 3.07 and their average for 5 years is 2.09.
What is Ikena Oncology Net EPS?
Ikena Oncology’s net earnings for the most recent quarter was -1.14$, which represents a 77.99% increase over the same period last year.
Who are Ikena Oncology Competitors?
Based on Jika.io AI model, Checkpoint Therapeutics, Corvus Pharmaceuticals, ESSA Pharma, Jounce Therapeutics, Kronos Bio, Leap Therapeutics, Molecular Partners AG, Viracta Therapeutics are considered to be Ikena Oncology’s competitors because the companies operate within the same industry as Ikena Oncology and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Ikena Oncology.
Who is Ikena Oncology’s Biggest competitor?
The biggest competitor of Ikena Oncology is Checkpoint Therapeutics, based on the Jika.io AI model. it has a similar market capitalization to Ikena Oncology within the industry, it dominates a similar share of the market as Ikena Oncology, and it provides and markets very similar services.
What industry is Ikena Oncology in?
Ikena Oncology is part of the biotechnology and healthcare industry.
Ikena Oncology vs Checkpoint Therapeutics
Market Cap: Ikena Oncology’s Market Cap of 179178736 is higher than Checkpoint Therapeutics Market Cap of 92846928.
Average Volume: Ikena Oncology’s Average Volume of 295585.0 is lower than Checkpoint Therapeutics Average Volume of 553926.0.
Beta: Ikena Oncology’s Beta of 0.0 is lower than Checkpoint Therapeutics Beta of 1.7.
Revenue: Ikena Oncology’s Revenue of 30.985M is higher than Checkpoint Therapeutics Revenue of 0.0.
Net Income: Ikena Oncology’s Net Income of -34.115M is lower than Checkpoint Therapeutics Net Income of -56.67M.
Gross Profit: Ikena Oncology’s Gross Profit of 0.0 is lower than Checkpoint Therapeutics Gross Profit of 0.0.
Ebitda: Ikena Oncology’s Ebitda of -33.571M is lower than Checkpoint Therapeutics Ebitda of -56.723M.
P/E Ratio: Ikena Oncology’s P/E Ratio of 6.04 is higher than Checkpoint Therapeutics P/E Ratio of -1.29.
P/S Ratio: Ikena Oncology’s P/S Ratio of 5.15 is higher than Checkpoint Therapeutics P/S Ratio of 367.59.
P/B Ratio: Ikena Oncology’s P/B Ratio of 0.82 is lower than Checkpoint Therapeutics P/B Ratio of 4.29.
P/FCF Ratio: Ikena Oncology’s P/FCF Ratio of -2.35 is higher than Checkpoint Therapeutics P/FCF Ratio of -2.1.
ROE: Ikena Oncology’s ROE of -0.2 is lower than Checkpoint Therapeutics ROE of -1.73.
ROA: Ikena Oncology’s ROA of -0.18 is lower than Checkpoint Therapeutics ROA of -1.56.
Return On Capital Employed: Ikena Oncology’s Return On Capital Employed of -0.2 is lower than Checkpoint Therapeutics Return On Capital Employed of -3.32.
Gross Profit Margin: Ikena Oncology’s Gross Profit Margin of 0.0 is lower than Checkpoint Therapeutics Gross Profit Margin of 0.0.
Assets (Total): Ikena Oncology’s Assets (Total) of 247.879M is lower than Checkpoint Therapeutics Assets (Total) of 55.728M.
Debt (Total): Ikena Oncology’s Debt (Total) of 6.986M is higher than Checkpoint Therapeutics Debt (Total) of 0.0.
Ikena Oncology vs Corvus Pharmaceuticals
Market Cap: Ikena Oncology’s Market Cap of 179178736 is higher than Corvus Pharmaceuticals Market Cap of 50277780.
Average Volume: Ikena Oncology’s Average Volume of 295585.0 is higher than Corvus Pharmaceuticals Average Volume of 258578.0.
Beta: Ikena Oncology’s Beta of 0.0 is lower than Corvus Pharmaceuticals Beta of 1.07.
Revenue: Ikena Oncology’s Revenue of 30.985M is higher than Corvus Pharmaceuticals Revenue of 0.0.
Net Income: Ikena Oncology’s Net Income of -34.115M is lower than Corvus Pharmaceuticals Net Income of -43.241M.
Gross Profit: Ikena Oncology’s Gross Profit of 0.0 is lower than Corvus Pharmaceuticals Gross Profit of 0.0.
Ebitda: Ikena Oncology’s Ebitda of -33.571M is lower than Corvus Pharmaceuticals Ebitda of -38.63M.
P/E Ratio: Ikena Oncology’s P/E Ratio of 6.04 is higher than Corvus Pharmaceuticals P/E Ratio of -1.26.
P/B Ratio: Ikena Oncology’s P/B Ratio of 0.82 is higher than Corvus Pharmaceuticals P/B Ratio of 0.56.
P/FCF Ratio: Ikena Oncology’s P/FCF Ratio of -2.35 is higher than Corvus Pharmaceuticals P/FCF Ratio of -1.83.
ROE: Ikena Oncology’s ROE of -0.2 is lower than Corvus Pharmaceuticals ROE of -0.41.
ROA: Ikena Oncology’s ROA of -0.18 is lower than Corvus Pharmaceuticals ROA of -0.39.
Return On Capital Employed: Ikena Oncology’s Return On Capital Employed of -0.2 is lower than Corvus Pharmaceuticals Return On Capital Employed of -0.38.
Assets (Total): Ikena Oncology’s Assets (Total) of 247.879M is higher than Corvus Pharmaceuticals Assets (Total) of 109.455M.
Debt (Total): Ikena Oncology’s Debt (Total) of 6.986M is higher than Corvus Pharmaceuticals Debt (Total) of 3.647M.
Shareholders Equity: Ikena Oncology’s Shareholders Equity of 207.877M is lower than Corvus Pharmaceuticals Shareholders Equity of 97.162M.
Ikena Oncology vs ESSA Pharma
Market Cap: Ikena Oncology’s Market Cap of 179178736 is higher than ESSA Pharma Market Cap of 113674024.
Average Volume: Ikena Oncology’s Average Volume of 295585.0 is higher than ESSA Pharma Average Volume of 195196.0.
Beta: Ikena Oncology’s Beta of 0.0 is lower than ESSA Pharma Beta of 1.58.
Revenue: Ikena Oncology’s Revenue of 30.985M is higher than ESSA Pharma Revenue of 0.0.
Net Income: Ikena Oncology’s Net Income of -34.115M is lower than ESSA Pharma Net Income of -36.805M.
Gross Profit: Ikena Oncology’s Gross Profit of 0.0 is lower than ESSA Pharma Gross Profit of 0.0.
Ebitda: Ikena Oncology’s Ebitda of -33.571M is lower than ESSA Pharma Ebitda of -36.799M.
P/E Ratio: Ikena Oncology’s P/E Ratio of 6.04 is higher than ESSA Pharma P/E Ratio of -3.05.
P/B Ratio: Ikena Oncology’s P/B Ratio of 0.82 is higher than ESSA Pharma P/B Ratio of 0.64.
P/FCF Ratio: Ikena Oncology’s P/FCF Ratio of -2.35 is lower than ESSA Pharma P/FCF Ratio of -4.04.
ROE: Ikena Oncology’s ROE of -0.2 is lower than ESSA Pharma ROE of -0.2.
ROA: Ikena Oncology’s ROA of -0.18 is lower than ESSA Pharma ROA of -0.2.
Return On Capital Employed: Ikena Oncology’s Return On Capital Employed of -0.2 is lower than ESSA Pharma Return On Capital Employed of -0.22.
Assets (Total): Ikena Oncology’s Assets (Total) of 247.879M is higher than ESSA Pharma Assets (Total) of 198.166M.
Debt (Total): Ikena Oncology’s Debt (Total) of 6.986M is higher than ESSA Pharma Debt (Total) of 330970.0.
Shareholders Equity: Ikena Oncology’s Shareholders Equity of 207.877M is higher than ESSA Pharma Shareholders Equity of 194.006M.
Ikena Oncology vs Jounce Therapeutics
Market Cap: Ikena Oncology’s Market Cap of 179178736 is higher than Jounce Therapeutics Market Cap of 168458224.
Average Volume: Ikena Oncology’s Average Volume of 295585.0 is lower than Jounce Therapeutics Average Volume of 354821.0.
Beta: Ikena Oncology’s Beta of 0.0 is lower than Jounce Therapeutics Beta of 1.15.
Revenue: Ikena Oncology’s Revenue of 30.985M is higher than Jounce Therapeutics Revenue of 26907.0.
Net Income: Ikena Oncology’s Net Income of -34.115M is lower than Jounce Therapeutics Net Income of -90872.0.
Gross Profit: Ikena Oncology’s Gross Profit of 0.0 is lower than Jounce Therapeutics Gross Profit of 0.0.
Ebitda: Ikena Oncology’s Ebitda of -33.571M is lower than Jounce Therapeutics Ebitda of 2.736M.
P/E Ratio: Ikena Oncology’s P/E Ratio of 6.04 is higher than Jounce Therapeutics P/E Ratio of -2.36.
P/S Ratio: Ikena Oncology’s P/S Ratio of 5.15 is lower than Jounce Therapeutics P/S Ratio of 6.64.
P/B Ratio: Ikena Oncology’s P/B Ratio of 0.82 is lower than Jounce Therapeutics P/B Ratio of 0.89.
P/FCF Ratio: Ikena Oncology’s P/FCF Ratio of -2.35 is higher than Jounce Therapeutics P/FCF Ratio of -2.02.
ROE: Ikena Oncology’s ROE of -0.2 is lower than Jounce Therapeutics ROE of -0.3.
ROA: Ikena Oncology’s ROA of -0.18 is lower than Jounce Therapeutics ROA of -0.33.
Return On Capital Employed: Ikena Oncology’s Return On Capital Employed of -0.2 is lower than Jounce Therapeutics Return On Capital Employed of -0.51.
Gross Profit Margin: Ikena Oncology’s Gross Profit Margin of 0.0 is lower than Jounce Therapeutics Gross Profit Margin of 0.0.
Assets (Total): Ikena Oncology’s Assets (Total) of 247.879M is lower than Jounce Therapeutics Assets (Total) of 252.696M.
Debt (Total): Ikena Oncology’s Debt (Total) of 6.986M is higher than Jounce Therapeutics Debt (Total) of 17.383M.
About Ikena Oncology
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. the lead target oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. it also develops a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of the aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. the company was established in 2016 and is headquartered in Boston, Massachusetts.
